Annual FCF
-$13.01 M
+$720.00 K+5.24%
December 1, 2023
Summary
- As of February 7, 2025, PSTV annual free cash flow is -$13.01 million, with the most recent change of +$720.00 thousand (+5.24%) on December 1, 2023.
- During the last 3 years, PSTV annual FCF has fallen by -$4.08 million (-45.75%).
- PSTV annual FCF is now -754.30% below its all-time high of -$1.52 million, reached on December 31, 1998.
Performance
PSTV Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$3.69 M
-$1.92 M-108.00%
September 1, 2024
Summary
- As of February 7, 2025, PSTV quarterly free cash flow is -$3.69 million, with the most recent change of -$1.92 million (-108.00%) on September 1, 2024.
- Over the past year, PSTV quarterly FCF has increased by +$859.00 thousand (+18.87%).
- PSTV quarterly FCF is now -200.38% below its all-time high of $3.68 million, reached on June 30, 2005.
Performance
PSTV Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$11.95 M
-$1.28 M-12.05%
September 1, 2024
Summary
- As of February 7, 2025, PSTV TTM free cash flow is -$11.95 million, with the most recent change of -$1.28 million (-12.05%) on September 1, 2024.
- Over the past year, PSTV TTM FCF has dropped by -$272.00 thousand (-2.33%).
- PSTV TTM FCF is now -457.77% below its all-time high of $3.34 million, reached on March 31, 2006.
Performance
PSTV TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
PSTV Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +5.2% | +18.9% | -2.3% |
| 3 y3 years | -45.8% | +17.0% | -1.4% |
| 5 y5 years | -7.5% | +17.0% | -1.4% |
PSTV Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -24.8% | +5.2% | -108.0% | +37.3% | -14.6% | +21.3% |
| 5 y | 5-year | -117.8% | +5.2% | -478.1% | +37.3% | -183.8% | +21.3% |
| alltime | all time | -754.3% | +63.7% | -200.4% | +65.5% | -457.8% | +67.3% |
Plus Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$3.69 M(+108.0%) | -$11.95 M(+12.1%) |
| Jun 2024 | - | -$1.78 M(-61.0%) | -$10.66 M(-8.7%) |
| Mar 2024 | - | -$4.55 M(+136.8%) | -$11.67 M(-10.3%) |
| Dec 2023 | -$13.01 M(-5.2%) | -$1.92 M(-20.2%) | -$13.01 M(-2.4%) |
| Sep 2023 | - | -$2.41 M(-13.6%) | -$13.33 M(-12.2%) |
| Jun 2023 | - | -$2.79 M(-52.6%) | -$15.18 M(+0.1%) |
| Mar 2023 | - | -$5.89 M(+162.4%) | -$15.17 M(+10.5%) |
| Dec 2022 | -$13.73 M(+31.7%) | -$2.25 M(-47.2%) | -$13.73 M(-2.8%) |
| Sep 2022 | - | -$4.25 M(+53.2%) | -$14.12 M(+16.0%) |
| Jun 2022 | - | -$2.78 M(-37.6%) | -$12.17 M(+3.2%) |
| Mar 2022 | - | -$4.45 M(+69.1%) | -$11.79 M(+13.1%) |
| Dec 2021 | -$10.42 M(+16.8%) | -$2.63 M(+14.3%) | -$10.42 M(-5.8%) |
| Sep 2021 | - | -$2.31 M(-3.8%) | -$11.07 M(-0.1%) |
| Jun 2021 | - | -$2.40 M(-22.5%) | -$11.08 M(+5.5%) |
| Mar 2021 | - | -$3.09 M(-5.8%) | -$10.50 M(+17.7%) |
| Dec 2020 | -$8.93 M(+49.5%) | -$3.28 M(+41.8%) | -$8.93 M(+91.2%) |
| Sep 2020 | - | -$2.31 M(+27.0%) | -$4.67 M(-4.3%) |
| Jun 2020 | - | -$1.82 M(+20.4%) | -$4.88 M(+15.9%) |
| Mar 2020 | - | -$1.51 M(-254.9%) | -$4.21 M(-29.5%) |
| Dec 2019 | -$5.97 M(-50.7%) | $977.00 K(-138.7%) | -$5.97 M(-36.7%) |
| Sep 2019 | - | -$2.52 M(+119.5%) | -$9.44 M(-1.8%) |
| Jun 2019 | - | -$1.15 M(-64.9%) | -$9.62 M(-14.2%) |
| Mar 2019 | - | -$3.28 M(+31.4%) | -$11.21 M(-7.4%) |
| Dec 2018 | -$12.11 M(-38.3%) | -$2.49 M(-7.6%) | -$12.11 M(-12.7%) |
| Sep 2018 | - | -$2.70 M(-1.8%) | -$13.86 M(-9.9%) |
| Jun 2018 | - | -$2.75 M(-34.2%) | -$15.39 M(-13.6%) |
| Mar 2018 | - | -$4.17 M(-1.8%) | -$17.81 M(-9.3%) |
| Dec 2017 | -$19.62 M(+0.1%) | -$4.25 M(+0.5%) | -$19.62 M(+0.7%) |
| Sep 2017 | - | -$4.22 M(-18.1%) | -$19.49 M(-2.1%) |
| Jun 2017 | - | -$5.16 M(-13.8%) | -$19.91 M(-2.7%) |
| Mar 2017 | - | -$5.99 M(+45.5%) | -$20.46 M(+4.4%) |
| Dec 2016 | -$19.60 M(-7.1%) | -$4.12 M(-11.3%) | -$19.60 M(-2.3%) |
| Sep 2016 | - | -$4.64 M(-18.7%) | -$20.07 M(-7.2%) |
| Jun 2016 | - | -$5.71 M(+11.4%) | -$21.63 M(+3.0%) |
| Mar 2016 | - | -$5.13 M(+11.7%) | -$21.00 M(-0.4%) |
| Dec 2015 | -$21.09 M(-32.7%) | -$4.59 M(-26.0%) | -$21.09 M(-1.6%) |
| Sep 2015 | - | -$6.21 M(+22.1%) | -$21.43 M(-6.0%) |
| Jun 2015 | - | -$5.08 M(-2.6%) | -$22.79 M(-16.1%) |
| Mar 2015 | - | -$5.22 M(+5.9%) | -$27.16 M(-13.4%) |
| Dec 2014 | -$31.35 M(-10.6%) | -$4.93 M(-34.8%) | -$31.35 M(-12.7%) |
| Sep 2014 | - | -$7.56 M(-20.0%) | -$35.90 M(-1.6%) |
| Jun 2014 | - | -$9.46 M(+0.5%) | -$36.49 M(+3.9%) |
| Mar 2014 | - | -$9.40 M(-0.8%) | -$35.11 M(+0.1%) |
| Dec 2013 | -$35.08 M(+5.0%) | -$9.48 M(+16.3%) | -$35.08 M(+3.1%) |
| Sep 2013 | - | -$8.15 M(+1.0%) | -$34.04 M(+0.1%) |
| Jun 2013 | - | -$8.07 M(-13.9%) | -$34.00 M(-3.0%) |
| Mar 2013 | - | -$9.38 M(+11.0%) | -$35.03 M(+4.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2012 | -$33.40 M(-6.9%) | -$8.44 M(+4.1%) | -$33.40 M(+1.3%) |
| Sep 2012 | - | -$8.11 M(-10.9%) | -$32.95 M(+0.6%) |
| Jun 2012 | - | -$9.11 M(+17.7%) | -$32.76 M(-0.5%) |
| Mar 2012 | - | -$7.74 M(-3.3%) | -$32.93 M(-8.2%) |
| Dec 2011 | -$35.88 M(+48.4%) | -$8.00 M(+1.1%) | -$35.88 M(+9.4%) |
| Sep 2011 | - | -$7.92 M(-14.6%) | -$32.79 M(+2.8%) |
| Jun 2011 | - | -$9.27 M(-13.3%) | -$31.90 M(+16.9%) |
| Mar 2011 | - | -$10.70 M(+118.0%) | -$27.28 M(+12.8%) |
| Dec 2010 | -$24.18 M(+0.6%) | -$4.91 M(-30.2%) | -$24.18 M(-5.3%) |
| Sep 2010 | - | -$7.03 M(+51.0%) | -$25.53 M(+5.5%) |
| Jun 2010 | - | -$4.65 M(-38.7%) | -$24.21 M(-5.2%) |
| Mar 2010 | - | -$7.59 M(+21.6%) | -$25.54 M(+6.3%) |
| Dec 2009 | -$24.03 M(-28.9%) | -$6.25 M(+9.4%) | -$24.03 M(-4.5%) |
| Sep 2009 | - | -$5.71 M(-4.7%) | -$25.15 M(-8.1%) |
| Jun 2009 | - | -$5.99 M(-1.6%) | -$27.37 M(-10.3%) |
| Mar 2009 | - | -$6.08 M(-17.4%) | -$30.53 M(-9.6%) |
| Dec 2008 | -$33.78 M(+10.6%) | -$7.37 M(-7.1%) | -$33.78 M(+0.6%) |
| Sep 2008 | - | -$7.93 M(-13.2%) | -$33.59 M(-0.2%) |
| Jun 2008 | - | -$9.14 M(-2.1%) | -$33.66 M(+6.5%) |
| Mar 2008 | - | -$9.34 M(+30.1%) | -$31.61 M(+3.4%) |
| Dec 2007 | -$30.56 M(+55.7%) | -$7.18 M(-10.3%) | -$30.56 M(+4.2%) |
| Sep 2007 | - | -$8.01 M(+13.0%) | -$29.32 M(+2.9%) |
| Jun 2007 | - | -$7.08 M(-14.5%) | -$28.48 M(-2.4%) |
| Mar 2007 | - | -$8.29 M(+39.7%) | -$29.18 M(+48.7%) |
| Dec 2006 | -$19.62 M(+565.8%) | -$5.94 M(-17.2%) | -$19.62 M(+94.5%) |
| Sep 2006 | - | -$7.17 M(-7.9%) | -$10.09 M(+24.1%) |
| Jun 2006 | - | -$7.78 M(-715.3%) | -$8.13 M(-343.3%) |
| Mar 2006 | - | $1.26 M(-64.9%) | $3.34 M(-213.3%) |
| Dec 2005 | -$2.95 M(-77.9%) | $3.60 M(-169.1%) | -$2.95 M(-70.1%) |
| Sep 2005 | - | -$5.21 M(-241.4%) | -$9.85 M(+35.7%) |
| Jun 2005 | - | $3.68 M(-173.3%) | -$7.26 M(-51.2%) |
| Mar 2005 | - | -$5.02 M(+52.1%) | -$14.87 M(+11.3%) |
| Dec 2004 | -$13.36 M(+48.7%) | -$3.30 M(+26.3%) | -$13.36 M(+19.9%) |
| Sep 2004 | - | -$2.61 M(-33.5%) | -$11.14 M(+1.8%) |
| Jun 2004 | - | -$3.93 M(+11.9%) | -$10.95 M(+30.2%) |
| Mar 2004 | - | -$3.51 M(+224.2%) | -$8.41 M(-6.5%) |
| Dec 2003 | -$8.99 M(+15.3%) | -$1.08 M(-55.1%) | -$8.99 M(-9.8%) |
| Sep 2003 | - | -$2.41 M(+73.0%) | -$9.96 M(+24.3%) |
| Jun 2003 | - | -$1.40 M(-65.9%) | -$8.02 M(-15.5%) |
| Mar 2003 | - | -$4.09 M(+98.8%) | -$9.49 M(+21.7%) |
| Dec 2002 | -$7.79 M(-29.0%) | -$2.06 M(+342.1%) | -$7.79 M(+35.9%) |
| Sep 2002 | - | -$466.00 K(-83.7%) | -$5.74 M(+8.8%) |
| Jun 2002 | - | -$2.87 M(+19.3%) | -$5.27 M(+119.3%) |
| Mar 2002 | - | -$2.40 M | -$2.40 M |
| Dec 2001 | -$10.99 M(+92.3%) | - | - |
| Dec 2000 | -$5.71 M(+11.9%) | - | - |
| Dec 1999 | -$5.11 M(+235.3%) | - | - |
| Dec 1998 | -$1.52 M | - | - |
FAQ
- What is Plus Therapeutics annual free cash flow?
- What is the all time high annual FCF for Plus Therapeutics?
- What is Plus Therapeutics annual FCF year-on-year change?
- What is Plus Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Plus Therapeutics?
- What is Plus Therapeutics quarterly FCF year-on-year change?
- What is Plus Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Plus Therapeutics?
- What is Plus Therapeutics TTM FCF year-on-year change?
What is Plus Therapeutics annual free cash flow?
The current annual FCF of PSTV is -$13.01 M
What is the all time high annual FCF for Plus Therapeutics?
Plus Therapeutics all-time high annual free cash flow is -$1.52 M
What is Plus Therapeutics annual FCF year-on-year change?
Over the past year, PSTV annual free cash flow has changed by +$720.00 K (+5.24%)
What is Plus Therapeutics quarterly free cash flow?
The current quarterly FCF of PSTV is -$3.69 M
What is the all time high quarterly FCF for Plus Therapeutics?
Plus Therapeutics all-time high quarterly free cash flow is $3.68 M
What is Plus Therapeutics quarterly FCF year-on-year change?
Over the past year, PSTV quarterly free cash flow has changed by +$859.00 K (+18.87%)
What is Plus Therapeutics TTM free cash flow?
The current TTM FCF of PSTV is -$11.95 M
What is the all time high TTM FCF for Plus Therapeutics?
Plus Therapeutics all-time high TTM free cash flow is $3.34 M
What is Plus Therapeutics TTM FCF year-on-year change?
Over the past year, PSTV TTM free cash flow has changed by -$272.00 K (-2.33%)